Sponsors Press Right to Appeal IRB Denials Directly to HHS

Executive Briefing Series
Clinical trial sponsors should be allowed to appeal institutional review board (IRB) denials directly to the HHS, stipulate that only one IRB need oversee multi-site studies and standardize the content of trial data submissions, according to comments on a proposed rule.

To View This Article:


Buy This Article Now

Add this article to your cart for $40.00